News Medical on MSN

Pre-surgical medication use grows for pancreatic, gynecologic, and abdominal lining cancers

The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a ...
InvestorsHub on MSN

BioVaxys posts encouraging ovarian cancer data from MVP-S combo trial

BioVaxys Technology Corp. (CSE:BIOV) (USOTC:BVAXF) said it has reported positive early results from its Phase 1B/2 PESCO ...
Cancer Therapy Advisor

New ACS Report Shows Sharp Drop in All-Cause Deaths From Cancer

Survival rates for all cancers are increasing, but threats to federal funding and access to care jeopardize these advances.

Cancer Deaths in Young People Are Falling, Except for 1 Type

A study published January 22 analyzed data from the National Center for Health Statistics.
Nature

Cancer might protect against Alzheimer’s — this protein helps explain why

A molecule produced by cancer cells can shield the brain from Alzheimer’s disease in mice. For decades, researchers have ...

B.C. mom with Stage 4 cancer says months-long wait to see oncologist put her at risk

A Port Moody, B.C., mother of two says she had to wait three months after being diagnosed with breast cancer to see an oncologist. She worries that wait has cost her precious time. B.C. Cancer data ...
pharmaphorum

Data builds behind Moderna's skin cancer vaccine

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...
Stocktwits on MSN

Moderna stock still worth 37% less after cancer vaccine data? BofA’s new price target keeps retail traders cautious

BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares. ・The update followed the ...

Do Cellphones Cause Cancer? RFK Jr.'s HHS Is Suppressing FDA Data Confirming Cellphone Safety.

Since cellphones tend to be held close to users' heads, brain cancer is one of the main concerns for alarmists like the ...
pharmaphorum

Ovarian cancer data restore faith in Corcept's relacorilant

After Corcept Therapeutics setback with relacorilant in Cushing syndrome last month, the company has bounced back with strong data in ovarian cancer, firming its share price. Corcept's stock fell ...